Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial

R. Roberts, C. Croft, H. K. Gold, T. D. Hartwell, Allan S Jaffe, J. E. Muller, S. M. Mullin, C. Parker, E. R. Passamani, W. K. Poole

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

A multicenter randomized single-blind study was performed to evaluate the effects of propranolol administered during the evolution of myocardial infarction. Five centers enrolled a total of 269 patients, with 134 receiving propranolol and 135 placebo. Propranolol or placebo was given intravenously upon randomization (0.1 mg per kilogram of body weight) and then orally for nine days to keep the heart rate between 45 and 60 beats per minute. Less than 2 per cent of patients were treated within 4 hours after the onset of symptoms, but 50 per cent received therapy within 8 hours of onset of chest pain, and the remainder between 8 and 18 hours. The heart rates in the propranolol-treated group were significantly lower than those in the placebo group (P<0.001). Base-line characteristics, including the mean heart rate (79.6 vs. 81.3) and the left ventricular ejection fraction (49.0 vs. 49.5), were similar in the two groups. The primary end point evaluated - infarct size as estimated from plasma MB creatine kinase activity - was virtually identical in the two groups, averaging 13.3 and 13.6 gram-equivalents of MB creatine kinase per square meter of body-surface area. Peak plasma levels of the enzyme were also similar in the two groups. No significant difference was observed between the propranolol and placebo groups in the change in left ventricular ejection fraction, extent of area involved in pyrophosphate uptake, R-wave loss on electrocardiograms, or mortality (after three years). These results do not support the use of propranolol administered four or more hours after the onset of symptoms to limit infarct size.

Original languageEnglish (US)
Pages (from-to)218-225
Number of pages8
JournalNew England Journal of Medicine
Volume311
Issue number4
StatePublished - 1984
Externally publishedYes

Fingerprint

Propranolol
Multicenter Studies
Myocardial Infarction
Placebos
MB Form Creatine Kinase
Heart Rate
Stroke Volume
Single-Blind Method
Body Surface Area
Random Allocation
Chest Pain
Electrocardiography
Body Weight
Mortality
Enzymes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Roberts, R., Croft, C., Gold, H. K., Hartwell, T. D., Jaffe, A. S., Muller, J. E., ... Poole, W. K. (1984). Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. New England Journal of Medicine, 311(4), 218-225.

Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. / Roberts, R.; Croft, C.; Gold, H. K.; Hartwell, T. D.; Jaffe, Allan S; Muller, J. E.; Mullin, S. M.; Parker, C.; Passamani, E. R.; Poole, W. K.

In: New England Journal of Medicine, Vol. 311, No. 4, 1984, p. 218-225.

Research output: Contribution to journalArticle

Roberts, R, Croft, C, Gold, HK, Hartwell, TD, Jaffe, AS, Muller, JE, Mullin, SM, Parker, C, Passamani, ER & Poole, WK 1984, 'Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial', New England Journal of Medicine, vol. 311, no. 4, pp. 218-225.
Roberts, R. ; Croft, C. ; Gold, H. K. ; Hartwell, T. D. ; Jaffe, Allan S ; Muller, J. E. ; Mullin, S. M. ; Parker, C. ; Passamani, E. R. ; Poole, W. K. / Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial. In: New England Journal of Medicine. 1984 ; Vol. 311, No. 4. pp. 218-225.
@article{e8c7db199f534522b1e0786b1227e61a,
title = "Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial",
abstract = "A multicenter randomized single-blind study was performed to evaluate the effects of propranolol administered during the evolution of myocardial infarction. Five centers enrolled a total of 269 patients, with 134 receiving propranolol and 135 placebo. Propranolol or placebo was given intravenously upon randomization (0.1 mg per kilogram of body weight) and then orally for nine days to keep the heart rate between 45 and 60 beats per minute. Less than 2 per cent of patients were treated within 4 hours after the onset of symptoms, but 50 per cent received therapy within 8 hours of onset of chest pain, and the remainder between 8 and 18 hours. The heart rates in the propranolol-treated group were significantly lower than those in the placebo group (P<0.001). Base-line characteristics, including the mean heart rate (79.6 vs. 81.3) and the left ventricular ejection fraction (49.0 vs. 49.5), were similar in the two groups. The primary end point evaluated - infarct size as estimated from plasma MB creatine kinase activity - was virtually identical in the two groups, averaging 13.3 and 13.6 gram-equivalents of MB creatine kinase per square meter of body-surface area. Peak plasma levels of the enzyme were also similar in the two groups. No significant difference was observed between the propranolol and placebo groups in the change in left ventricular ejection fraction, extent of area involved in pyrophosphate uptake, R-wave loss on electrocardiograms, or mortality (after three years). These results do not support the use of propranolol administered four or more hours after the onset of symptoms to limit infarct size.",
author = "R. Roberts and C. Croft and Gold, {H. K.} and Hartwell, {T. D.} and Jaffe, {Allan S} and Muller, {J. E.} and Mullin, {S. M.} and C. Parker and Passamani, {E. R.} and Poole, {W. K.}",
year = "1984",
language = "English (US)",
volume = "311",
pages = "218--225",
journal = "New England Journal of Medicine",
issn = "1533-4406",
publisher = "Massachussetts Medical Society",
number = "4",

}

TY - JOUR

T1 - Effect of propranolol on myocardial-infarct size in a randomized blinded multicenter trial

AU - Roberts, R.

AU - Croft, C.

AU - Gold, H. K.

AU - Hartwell, T. D.

AU - Jaffe, Allan S

AU - Muller, J. E.

AU - Mullin, S. M.

AU - Parker, C.

AU - Passamani, E. R.

AU - Poole, W. K.

PY - 1984

Y1 - 1984

N2 - A multicenter randomized single-blind study was performed to evaluate the effects of propranolol administered during the evolution of myocardial infarction. Five centers enrolled a total of 269 patients, with 134 receiving propranolol and 135 placebo. Propranolol or placebo was given intravenously upon randomization (0.1 mg per kilogram of body weight) and then orally for nine days to keep the heart rate between 45 and 60 beats per minute. Less than 2 per cent of patients were treated within 4 hours after the onset of symptoms, but 50 per cent received therapy within 8 hours of onset of chest pain, and the remainder between 8 and 18 hours. The heart rates in the propranolol-treated group were significantly lower than those in the placebo group (P<0.001). Base-line characteristics, including the mean heart rate (79.6 vs. 81.3) and the left ventricular ejection fraction (49.0 vs. 49.5), were similar in the two groups. The primary end point evaluated - infarct size as estimated from plasma MB creatine kinase activity - was virtually identical in the two groups, averaging 13.3 and 13.6 gram-equivalents of MB creatine kinase per square meter of body-surface area. Peak plasma levels of the enzyme were also similar in the two groups. No significant difference was observed between the propranolol and placebo groups in the change in left ventricular ejection fraction, extent of area involved in pyrophosphate uptake, R-wave loss on electrocardiograms, or mortality (after three years). These results do not support the use of propranolol administered four or more hours after the onset of symptoms to limit infarct size.

AB - A multicenter randomized single-blind study was performed to evaluate the effects of propranolol administered during the evolution of myocardial infarction. Five centers enrolled a total of 269 patients, with 134 receiving propranolol and 135 placebo. Propranolol or placebo was given intravenously upon randomization (0.1 mg per kilogram of body weight) and then orally for nine days to keep the heart rate between 45 and 60 beats per minute. Less than 2 per cent of patients were treated within 4 hours after the onset of symptoms, but 50 per cent received therapy within 8 hours of onset of chest pain, and the remainder between 8 and 18 hours. The heart rates in the propranolol-treated group were significantly lower than those in the placebo group (P<0.001). Base-line characteristics, including the mean heart rate (79.6 vs. 81.3) and the left ventricular ejection fraction (49.0 vs. 49.5), were similar in the two groups. The primary end point evaluated - infarct size as estimated from plasma MB creatine kinase activity - was virtually identical in the two groups, averaging 13.3 and 13.6 gram-equivalents of MB creatine kinase per square meter of body-surface area. Peak plasma levels of the enzyme were also similar in the two groups. No significant difference was observed between the propranolol and placebo groups in the change in left ventricular ejection fraction, extent of area involved in pyrophosphate uptake, R-wave loss on electrocardiograms, or mortality (after three years). These results do not support the use of propranolol administered four or more hours after the onset of symptoms to limit infarct size.

UR - http://www.scopus.com/inward/record.url?scp=0021229979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0021229979&partnerID=8YFLogxK

M3 - Article

C2 - 6377070

AN - SCOPUS:0021229979

VL - 311

SP - 218

EP - 225

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 1533-4406

IS - 4

ER -